TG THERAPEUTICS, INC. Payments to Acquire Held-to-maturity Securities
TG THERAPEUTICS, INC. (TGTX) reported Payments to Acquire Held-to-maturity Securities of $37.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2026-08-05
- TG THERAPEUTICS, INC. payments to acquire held-to-maturity securities for the quarter ending 2026-06-30 was $16.43M, a 69.18% decline year-over-year.
- TG THERAPEUTICS, INC. payments to acquire held-to-maturity securities for the quarter ending 2026-03-31 was $21.06M, a 77.12% decline year-over-year.
- TG THERAPEUTICS, INC. payments to acquire held-to-maturity securities for the quarter ending 2025-12-31 was $45.57M, a 21.28% decline year-over-year.
- TG THERAPEUTICS, INC. payments to acquire held-to-maturity securities for the quarter ending 2025-09-30 was $31.31M, a 69.11% decline year-over-year.
- TG THERAPEUTICS, INC. payments to acquire held-to-maturity securities for fiscal 2025 was $222.24M, a 28.43% decline from fiscal 2024.
- TG THERAPEUTICS, INC. payments to acquire held-to-maturity securities for fiscal 2024 was $310.52M, a 111.41% increase from fiscal 2023.
- TG THERAPEUTICS, INC. payments to acquire held-to-maturity securities for fiscal 2023 was $146.88M, a 36.92% increase from fiscal 2022.
- TG THERAPEUTICS, INC. payments to acquire held-to-maturity securities for fiscal 2022 was $107.27M, a 93.18% increase from fiscal 2021.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 12 month | Payments to Acquire Held-to-maturity Securities 25 month | Payments to Acquire Held-to-maturity Securities 28 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $37.49M 10-Q · filed 2026-08-05 | $83.06M derived: sum of 3 quarters · filed 2026-08-05 | $114.37M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $21.06M 10-Q · filed 2026-05-06 | $66.63M derived: sum of 2 quarters · filed 2026-05-06 | $97.94M derived: sum of 3 quarters · filed 2026-05-06 | $151.24M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $45.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $76.88M derived: sum of 2 quarters · filed 2026-02-27 | $130.18M derived: sum of 3 quarters · filed 2026-08-05 | $222.24M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $31.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $84.61M derived: sum of 2 quarters · filed 2026-08-05 | $176.67M 10-Q · filed 2025-11-05 | $234.56M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $53.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $145.36M 10-Q · filed 2026-08-05 | $203.25M derived: sum of 3 quarters · filed 2026-08-05 | $304.61M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $92.06M 10-Q · filed 2026-05-06 | $149.95M derived: sum of 2 quarters · filed 2026-05-06 | $251.31M derived: sum of 3 quarters · filed 2026-05-06 | $321.04M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $57.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $159.25M derived: sum of 2 quarters · filed 2026-02-27 | $228.99M derived: sum of 3 quarters · filed 2026-02-27 | $310.52M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $101.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $171.09M derived: sum of 2 quarters · filed 2025-11-05 | $252.63M 10-Q · filed 2025-11-05 | $321.06M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-06-30 | $69.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $151.26M 10-Q · filed 2025-08-08 | $219.70M derived: sum of 3 quarters · filed 2026-02-27 | $275.98M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-03-31 | $81.53M 10-Q · filed 2025-05-09 | $149.96M derived: sum of 2 quarters · filed 2026-02-27 | $206.24M derived: sum of 3 quarters · filed 2026-02-27 | $206.24M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2023-12-31 | $68.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $124.71M derived: sum of 2 quarters · filed 2026-02-27 | $124.71M derived: sum of 3 quarters · filed 2026-02-27 | $146.88M 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $56.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $56.28M derived: sum of 2 quarters · filed 2024-11-07 | $78.45M 10-Q · filed 2024-11-07 | $82.44M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $22.17M 10-Q · filed 2024-08-09 | $26.17M derived: sum of 3 quarters · filed 2025-03-03 | |||
| 2023-03-31 | $22.17M 10-Q · filed 2024-05-06 | $26.17M derived: sum of 2 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $107.27M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $103.28M 10-Q · filed 2023-11-06 | |||||
| 2021-12-31 | $55.53M 10-K · filed 2024-02-29 | |||||
| 2015-06-30 | $18.32M 10-Q · filed 2015-08-10 | |||||
| 2014-06-30 | $6.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $6.13M 10-Q · filed 2015-08-10 | ||||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-14 | $4.92M 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | $4.92M 10-K · filed 2014-03-07 | $4.92M 10-K · filed 2014-03-07 | ||||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-14 | |||||
| 2012-12-31 | $0.00 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |